Qiagen N.V. (QGEN)
| Market Cap | 9.93B |
| Revenue (ttm) | 1.97B |
| Net Income (ttm) | 92.93M |
| Shares Out | 222.26M |
| EPS (ttm) | 0.41 |
| PE Ratio | 107.74 |
| Forward PE | 19.92 |
| Dividend | $1.32 (2.96%) |
| Ex-Dividend Date | Jan 30, 2024 |
| Volume | 760,147 |
| Open | 43.84 |
| Previous Close | 44.32 |
| Day's Range | 43.78 - 44.95 |
| 52-Week Range | 39.03 - 47.44 |
| Beta | 0.37 |
| Analysts | Buy |
| Price Target | 51.42 (+15.11%) |
| Earnings Date | Feb 4, 2025 |
About QGEN
Qiagen N.V. offers sample to insight solutions that transform biological materials into molecular insights. The company provides sample technology consumables, such as nucleic stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids from secondary sample materials; and instruments for n... [Read more]
Financial Performance
In 2023, Qiagen's revenue was $1.97 billion, a decrease of -8.23% compared to the previous year's $2.14 billion. Earnings were $341.30 million, a decrease of -19.35%.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for QGEN stock is "Buy." The 12-month stock price forecast is $51.42, which is an increase of 15.11% from the latest price.
News
QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data
REDWOOD CITY, Calif. & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN, Frankfurt Prime Standard: QIA) today announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new featu...
QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has reached a significant milestone with over 1,000 placements of the EZ2 C...
QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing
BARCELONA, Spain & VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced plans to move its QIAstat-Dx operations within the Barcelona area to a ne...
QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis
QIAGEN introduces market's first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and custom NGS panels // First-of-its-kind Custo...
Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants John Gilardi - VP, Head of Corporate Communications and IR Thierry Bernard - CEO Roland Sacke...
Diagnostics firm Qiagen reports rise in third-quarter revenue
Qiagen reported a rise in third-quarter revenue on Wednesday, owing to strong sales of its diagnostic devices.
QIAGEN receives FDA clearance of QIAstat-Dx meningitis/encephalitis panel to support emergency diagnostics
QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth FDA clearance marks milestone in 2024 in successf...
QIAGEN receives FDA clearance for QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment
QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions // With the new test and the 21-targ...
QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications
Portfolio expansion reinforces QIAGEN's leadership in automated solutions for non-invasive liquid biopsy applications combined with complete workflows // New ccfDNA Kit upgrade with urine protocol for...
QIAGEN N.V. to release results for Q3 2024 and hold webcast
Venlo, The Netherlands, Oct. 10, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the third quarter 2024.
Global TB Summit 2024: QIAGEN leads the charge as tuberculosis reemerges as a leading infectious killer
QIAGEN's leading tuberculosis blood test QuantiFERON®-TB Gold Plus remains crucial for detection of latent tuberculosis infection, aiding in breaking the cycle of disease transmission // Over 35 top t...
QIAGEN launches QIAcuityDx digital PCR system for clinical testing in oncology
Expands range of applications for successful QIAcuity digital PCR platforms, now entering the clinical space across North America and the EU // Provides absolute quantitation, essential for precise mo...
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays
Product line earns CE-marking under new EU IVDR framework – including QIAstat-Dx Analyzer, QIAstat-Dx Rise and panels for detection of gastrointestinal and respiratory infections // Certification conf...
PreAnalytiX, a QIAGEN and BD joint venture, launches novel solution for liquid biopsy from urine samples
PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA stabilization from urine // QIAGEN to commercial...
QIAGEN and Bode Technology partner to advance use of GEDmatch PRO forensic genetic genealogy database
QIAGEN chooses Bode Technology as its exclusive global commercial partner to accelerate use of GEDmatch PRO genealogy database in law enforcement and identification of human remains // Collaboration e...
QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform
QIAGEN adds over 100 new validated QIAcuity digital PCR assays for cancer research, inherited genetic disorders, infectious disease surveillance, and other applications // QIAcuity digital PCR enables...
QIAGEN and Bio-Manguinhos/Fiocruz collaborate to enhance malaria and dengue detection in Brazil's national screening programs
Advanced PCR-based screening platform deployed nationwide across 30 laboratories provides new capabilities to detect malaria, HIV, HCV, and HBV in blood donations // Advanced capabilities support epid...
QIAGEN and Lilly collaborate to support development of a QIAstat-Dx IVD panel that identifies patients at risk for developing Alzheimer's disease
QIAGEN to develop the first QIAstat-Dx IVD panel for neurodegenerative applications // New QIAstat-Dx panel to identify APOE genotypes, one of many factors considered in the diagnosis of patients with...
QIAGEN N.V. announces conversion price of new net share settled convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION ...
QIAGEN N.V. announces successful placement of new net share settled convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION ...
QIAGEN N.V. launches non-US offering of net share settled convertible bonds
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION ...
QIAGEN expands QIAstat-Dx into precision medicine through partnership for companion diagnostics in chronic diseases
New agreement expands collaboration with AstraZeneca beyond oncology, including complex chronic diseases // QIAGEN's syndromic testing platform QIAstat-Dx enables specialty care providers to make fast...
Qiagen N.V. (QGEN) Q2 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN) Q2 2024 Earnings Call Transcript Q2 2024 Earnings Conference Call August 1, 2024 9:00 AM ET Company Participants John Gilardi - Investor Relations Thierry Bernard - Chief Exec...
QIAGEN delivers solid performance and exceeds outlook for Q2 2024
Q2 2024: Net sales of $496 million (+0% actual rates, +1% constant exchange rates, CER); net loss per share of $0.83 but adjusted diluted EPS of $0.55 // Net sales at CER of $502 million ahead of outl...
QIAGEN N.V. to release results for Q2 2024 and hold webcast
Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024.